Johnson & Johnson’s JNJ MedTech unit has temporarily paused sales of Varipulse, its pulsed field ablation (PFA) therapy to ...
Johnson & Johnson announced that on January 5, “out of an abundance of caution,” Johnson & Johnson MedTech temporarily paused the U.S.
The temporary halt to investigate reported neurovascular events comes two months after Johnson & Johnson won FDA approval for ...
The temporary pause will allow the company to investigate four neurovascular events seen in an external validation study.
Bernstein lowered the firm’s price target on Johnson & Johnson to $160 from $177 and keeps a Market Perform rating on the shares as part of ...
We came across a bullish thesis on Johnson & Johnson (NYSE:JNJ) on Business Model Mastery Substack by The Antifragile ...
In 2024, we saw another proactive year for some of the biggest names in medtech as they looked to bolster their ranks through ...
Johnson & Johnson MedTech announced that it has temporarily paused the United States External Evaluation and all United Stat ...
Boston Scientific is diving into the field of intravascular lithotripsy, with a $664 million deal to pick up Bolt Medical and ...